Advanced search
Publication Cover
Modern Rheumatology Volume 24, 2014 - Issue 1
Journal homepage
2,357
Views
91
CrossRef citations to date
0
Altmetric
Original Articles

Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study

Norihiro NishimotoOsaka Rheumatology Clinic, Tatsuno-Sinsaibashi-Building 5th Floor, 4-4-10 Minamisenba Chuo-ku, Osaka 542-0081, Japan;Department of Molecular Regulation for Intractable Disease, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan;Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, JapanCorrespondence[email protected] [email protected]
,
Koichi AmanoDepartment of Rheumatology/Clinical Immunology, Saitama Medical Centre, Saitama Medical University, Saitama, Japan
,
Yasuhiko HirabayashiDepartment of Rheumatology, Hikarigaoka Spellman Hospital, Sendai, Japan
,
Takahiko HoriuchiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
,
Tomonori IshiiDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Miyagi, Japan
,
Mitsuhiro IwahashiHigashihiroshima Memorial Hospital, Higashihiroshima, Japan
,
Masahiro IwamotoDivision of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan
,
Hitoshi KohsakaDepartment of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan
,
Masakazu KondoKondo Clinic of Rheumatology and Orthopaedic Surgery, Fukuoka, Japan
,
Tsukasa MatsubaraMatsubara Mayflower Hospital, Hyogo, Japan
,
Toshihide MimuraDepartment of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan
,
Hisaaki MiyaharaNational Hospital Organization Kyushu Medical Center, Fukuoka, Japan
,
Shuji OhtaDepartment of Rheumatology, Taga General Hospital, Ibaraki, Japan
,
Yukihiko SaekiNational Hospital Organization Osaka-Minami Medical Center, Osaka, Japan
,
Kazuyoshi SaitoThe First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan
,
Hajime SanoDivision of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
,
Kiyoshi TakasugiDohgo Spa Hospital, Ehime, Japan
,
Tsutomu TakeuchiDivision of Rheumatology and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Keio University, Tokyo, Japan
,
Shigeto TohmaSagamihara National Hospital, National Hospital Organization, Kanagawa, Japan
,
Tomomi TsuruPS Clinic, Fukuoka, Japan
,
Yukitaka UekiSasebo Chuo Hospital, Nagasaki, Japan
,
Jiro YamanaHigashihiroshima Memorial Hospital, Higashihiroshima, Japan
,
Jun HashimotoNational Hospital Organization Osaka-Minami Medical Center, Osaka, Japan
,
Takaji MatsutaniLaboratory of Immune Regulation, Wakayama Medical University, Wakayama, Japan
,
Miho MurakamiDepartment of Molecular Regulation for Intractable Disease, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan;Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, Japan
&
Nobuhiro TakagiChugai Pharmaceutical Co. Ltd., Tokyo, Japan
 show all
Pages 17-25 | Received 27 Sep 2011, Accepted 15 Apr 2013, Published online: 22 Nov 2013

Citations (91)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (13)

Masashi Narazaki & Tadamitsu Kishimoto. (2022) Current status and prospects of IL-6–targeting therapy. Expert Review of Clinical Pharmacology 15:5, pages 575-592.
Read now
Giulio Cavalli & Ennio Giulio Favalli. (2019) Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis. Expert Review of Clinical Immunology 15:12, pages 1313-1322.
Read now
MK Meyer, M Andersen, T Ring, GN Andersen, LH Ehlers, C Rasmussen & A Stensballe. (2019) Personalized rheumatic medicine through dose reduction reduces the cost of biological treatment – a retrospective intervention analysis. Scandinavian Journal of Rheumatology 48:5, pages 398-407.
Read now
Atsushi Ogata, Yasuhiro Kato, Shinji Higa & Keiji Maeda. (2019) Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis. Expert Opinion on Drug Delivery 16:6, pages 639-648.
Read now
Atsushi Ogata, Yasuhiro Kato, Shinji Higa & Kazuyuki Yoshizaki. (2019) IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. Modern Rheumatology 29:2, pages 258-267.
Read now
Motohiko Aizu, Ichiro Mizushima, Satoshi Nakazaki, Akikatsu Nakashima, Takashi Kato, Takashi Murayama, Shinichi Kato, Yasuo Katsuki, Kunihiro Ogane, Hiroshi Fujii, Kazunori Yamada, Hideki Nomura, Akihiro Yachie, Masakazu Yamagishi & Mitsuhiro Kawano. (2018) Changes in serum interleukin-6 levels as possible predictor of efficacy of tocilizumab treatment in rheumatoid arthritis. Modern Rheumatology 28:4, pages 592-598.
Read now
Jun Kikuchi, Tsuneo Kondo, Akiko Shibata, Ryota Sakai, Yusuke Okada, Kentaro Chino, Ayumi Okuyama, Takahiko Kurasawa, Hirofumi Takei & Koichi Amano. (2018) Efficacy and tolerability of six-week extended dosing interval with tocilizumab therapy in a prospective cohort as remission maintenance in patients with rheumatoid arthritis. Modern Rheumatology 28:3, pages 444-451.
Read now
Yosuke Hattori, Daihei Kida & Atsushi Kaneko. (2018) Steroid therapy and renal dysfunction are independently associated with serum levels of matrix metalloproteinase-3 in patients with rheumatoid arthritis. Modern Rheumatology 28:2, pages 242-248.
Read now
Yosuke Hattori, Toshihisa Kojima, Atsushi Kaneko, Daihei Kida, Yuji Hirano, Takayoshi Fujibayashi, Yuichiro Yabe, Takeshi Oguchi, Yasuhide Kanayama, Hiroyuki Miyake, Takefumi Kato, Hideki Takagi, Masatoshi Hayashi, Takayasu Ito, Tomone Shioura, Nobunori Takahashi, Hisato Ishikawa, Koji Funahashi & Naoki Ishiguro. (2018) High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab. Modern Rheumatology 28:1, pages 119-125.
Read now
Fabiola Atzeni, Maurizio Benucci, Rossella Talotta, Ignazio Francesco Masala, Piercarlo Sarzi-Puttini & Marcello Govoni. (2016) What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?. Expert Review of Clinical Pharmacology 9:11, pages 1403-1411.
Read now
Hisashi Yamanaka, Shouhei Nagaoka, Soo-Kon Lee, Sang-Cheol Bae, Tsuyoshi Kasama, Hitomi Kobayashi, Yuichi Nishioka, Yukitaka Ueki, Yohei Seto, Makoto Nishinarita, Naoto Tamura, Noriko Kimura, Kazuyoshi Saito, Tetsuya Tomita, Yasushi Nawata, Sadahiro Suzuki, Yoshiaki Ishigatsubo, Yasuhiko Munakata, Yuichi Makino, Eisuke Inoue, Yoshiya Tanaka & Tsutomu Takeuchi. (2016) Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity—results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology 26:5, pages 651-661.
Read now
Diederik De Cock, Kristien Van der Elst, Sabrina Meyfroidt, Patrick Verschueren & René Westhovens. (2015) The optimal combination therapy for the treatment of early rheumatoid arthritis. Expert Opinion on Pharmacotherapy 16:11, pages 1615-1625.
Read now
Emilio Besada. (2014) Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review. Patient Preference and Adherence 8, pages 1051-1059.
Read now

Articles from other publishers (78)

Fangfang Chen, Yitian Lang, Shikai Geng, Xiaodong Wang, Liangjing Lu, Shuang Ye, Le Zhang & Ting Li. (2023) The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis. Clinical Rheumatology 42:10, pages 2777-2786.
Crossref
Luuk van Esveld, Juul M Cox, T Martijn Kuijper, Tessa M Bosch & Angelique EAM Weel-Koenders. (2023) Cost–utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands. Annals of the Rheumatic Diseases, pages ard-2023-224190.
Crossref
Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B McInnes, Naveed Sattar, Tanja A Stamm, Tsutomu Takeuchi, Michael Trauner, Désirée van der Heijde, Marieke Voshaar, Kevin L Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Rüdiger R Burmester, Johannes WJ Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H Choy, Catalin Codreanu, Bernard Combe, Mary K Crow, Maarten de Wit, Paul Emery, Roy M Fleischmann, Cem Gabay, Merete Lund Hetland, Kimme L Hyrich, Annamaria Iagnocco, John D Isaacs, Joel M Kremer, Xavier Mariette, Peter A Merkel, Eduardo F Mysler, Peter Nash, Michael T Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka & Josef S Smolen. (2023) Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Annals of the Rheumatic Diseases 82:6, pages 773-787.
Crossref
Nedim Kaban & Halil Harman. (2023) Paradigm guiding to tapering or discontinuation of biologic and targeted synthetic disease‐modifying antirheumatic drugs in the treatment of patients with rheumatoid arthritis: Results from a local prospective study . International Journal of Rheumatic Diseases 26:4, pages 689-698.
Crossref
Eugen Feist & Evgeny Nasonov. (2023) Interleukin 6 Inhibition in Rheumatoid Arthritis: Highlight on Olokizumab. Rheumatology 2:1, pages 17.
Crossref
E. L. Nasonov & Eugen Feist. (2022) The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6). Rheumatology Science and Practice 60:5, pages 505-518.
Crossref
Eiji Sakashita, Katsuya Nagatani, Hitoshi Endo & Seiji Minota. (2022) Serum level of IFNβ distinguishes early from late relapses after biologics withdrawal in rheumatoid arthritis. Scientific Reports 12:1.
Crossref
Kastriot Kastrati, Daniel Aletaha, Gerd R Burmester, Eva Chwala, Christian Dejaco, Maxime Dougados, Iain B McInnes, Angelo Ravelli, Naveed Sattar, Tanja A Stamm, Tsutomu Takeuchi, Michael Trauner, Desirée van der Heijde, Marieke J H Voshaar, Kevin Winthrop, Josef S Smolen & Andreas Kerschbaumer. (2022) A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD Open 8:2, pages e002359.
Crossref
Rouman Zhang, Xiao-Po Tang, Jian Wang, Wei-Xiang Liu, Jian Liu, Yue Wang, Wei Liu, Yong-Fei Fang, Dong-Yi He, Ying Liu, Ming-Li Gao, Qing-Jun Wu, Zhen-Bin Li, Shi Chen, Qing-Chun Huang, Yan-Ming Xie, Jun-Li Zhang, Cai-Yun Zhou, Li Ma, Xin-Chang Wang, Quan Jiang & Xun Gong. (2022) The Impact of Traditional Chinese Medicine QingreHuoxue Treatment and the Combination of Methotrexate and Hydroxychloroquine on the Radiological Progression of Active Rheumatoid Arthritis: A 52-Week Follow-Up of a Randomized Controlled Clinical Study. Evidence-Based Complementary and Alternative Medicine 2022, pages 1-12.
Crossref
Simone Arnold, Veronika K Jaeger, Almut Scherer, Adrian Ciurea, Ulrich A Walker & Diego Kyburz. (2022) Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors. Rheumatology 61:1, pages 131-138.
Crossref
Hanna Gul, Kate Harnden & Benazir Saleem. (2021) Defining the Optimal Strategies for Achieving Drug-Free Remission in Rheumatoid Arthritis: A Narrative Review. Healthcare 9:12, pages 1726.
Crossref
Hideto Kameda, Ayako Hirata, Takaharu Katagiri, Yuto Takakura, Yuki Inoue, Sayaka Takenaka, Hideki Ito, Kennosuke Mizushina & Takehisa Ogura. (2021) Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission. Scientific Reports 11:1.
Crossref
Theresa Burkard, Ross D Williams, Enriqueta Vallejo-Yagüe, Thomas Hügle, Axel Finckh, Diego Kyburz & Andrea M Burden. (2021) Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients. Rheumatology Advances in Practice 5:3.
Crossref
Amal Saki, Elham Rajaei & Fakher Rahim. (2021) Safety and efficacy of tocilizumab for rheumatoid arthritis: a systematic review and metaanalysis of clinical trial studies. Rheumatology 59:3, pages 169-179.
Crossref
Jacques Morel, Anne Tournadre, Jérémie Sellam, Yoram Bouhnik, Divi Cornec, Valérie Devauchelle-Pensec, Philippe Dieudé, Philippe Goupille, Nicolas Kluger, Estibaliz Lazaro, Benoit Le Goff, Victor de Lédinghen, Thierry Lequerré, Gaëtane Nocturne, Raphaèle Seror, Marie-Elise Truchetet, Frank Verhoeven, Thao Pham & Christophe Richez. (2021) Practical management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine 88:4, pages 105221.
Crossref
Kenneth F Baker, Jasmine P X Sim & John D Isaacs. (2021) Biomarkers of tolerance in immune-mediated inflammatory diseases: a new era in clinical management?. The Lancet Rheumatology 3:5, pages e371-e382.
Crossref
Mario H. Cardiel, Sandra Carrillo, Marcela Pérez, Lilia Andrade, César Pacheco Tena, Luis H. Silveira, Leonardo Limón, Sergio Cerpa, Sergio Gutiérrez Ureña, Sergio Durán, Fedra Irazoque Palazuelos, Sandra Muñoz López, Sandra Araceli Sicsik Ayala, Leonor Barile, María Azucena Ramos Sánchez, Daniel Grajeda Portes, Margarita Portela, Alina Hernández Bedolla, José Luis García-Figueroa, Mauricio Montero, Carlos Abud-Mendoza, Marco Ulises Martínez Martínez, David Herrera van Ostdam, Virginia Pascual-Ramos, Javier Merayo-Chalico, Istar Guzmán-Sánchez, María Esther Pérez-Bastidas, Jorge Enrique Aguilar Arreola, Alejandra López Rodríguez, Greta Reyes-Cordero, Humberto Alfredo Ricardez, María Fernanda Hernández Cabrera, Guadalupe Olvera-Soto & Daniel Xibillé Friedmann. (2021) Update of the Mexican College of Rheumatology guidelines for the pharmacological treatment of rheumatoid arthritis, 2018. Reumatología Clínica (English Edition) 17:4, pages 215-228.
Crossref
Mario H. Cardiel, Sandra Carrillo, Marcela Pérez, Lilia Andrade, César Pacheco Tena, Luis H. Silveira, Leonardo Limón, Sergio Cerpa, Sergio Gutiérrez Ureña, Sergio Durán, Fedra Irazoque Palazuelos, Sandra Muñoz López, Sandra Araceli Sicsik Ayala, Leonor Barile, María Azucena Ramos Sánchez, Daniel Grajeda Portes, Margarita Portela, Alina Hernández Bedolla, José Luis García-Figueroa, Mauricio Montero, Carlos Abud-Mendoza, Marco Ulises Martínez Martínez, David Herrera van Ostdam, Virginia Pascual-Ramos, Javier Merayo-Chalico, Istar Guzmán-Sánchez, María Esther Pérez-Bastidas, Jorge Enrique Aguilar Arreola, Alejandra López Rodríguez, Greta Reyes-Cordero, Humberto Alfredo Ricardez, María Fernanda Hernández Cabrera, Guadalupe Olvera-Soto & Daniel Xibillé Friedmann. (2021) Actualización de las guías del tratamiento farmacológico de la artritis reumatoide del Colegio Mexicano de Reumatología 2018. Reumatología Clínica 17:4, pages 215-228.
Crossref
Jiaqi Zeng, Lihua Peng, Wei Zheng, Feng Huang, Nana Zhang, Di Wu & Yunsheng Yang. (2020) Fecal microbiota transplantation for rheumatoid arthritis: A case report. Clinical Case Reports 9:2, pages 906-909.
Crossref
Manivel Rengasamy & Rebecca B. Price. 2021. The Neuroscience of Depression. The Neuroscience of Depression 119 125 .
Chayma Ladhari, Pierre Le Blay, Thierry Vincent, Ahmed Larbi, Emma Rubenstein, Rosanna Ferreira Lopez, Christian Jorgensen & Yves-Marie Pers. (2020) Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study. BMC Rheumatology 4:1.
Crossref
Aprajita Jagpal & Jasvinder A. Singh. (2020) Treatment Guidelines in Rheumatoid Arthritis—Optimizing the Best of Both Worlds. Current Treatment Options in Rheumatology 6:4, pages 354-369.
Crossref
Jesús Tornero Molina, Alejandro Balsa Criado, Francisco Blanco García, Ricardo Blanco Alonso, Sagrario Bustabad, Jaime Calvo Alen, Héctor Corominas, Antonio Fernández Nebro, Jose Andrés Román Ivorra & Raimon Sanmartí. (2020) Expert recommendations on the interleukin 6 blockade in patients with rheumatoid arthritis. Reumatología Clínica (English Edition) 16:4, pages 272-281.
Crossref
Jesús Tornero Molina, Alejandro Balsa Criado, Francisco Blanco García, Ricardo Blanco Alonso, Sagrario Bustabad, Jaime Calvo Alen, Héctor Corominas, Antonio Fernández Nebro, Jose Andrés Román Ivorra & Raimon Sanmartí. (2020) Recomendaciones de experto sobre el bloqueo de la interleucina 6 en pacientes con artritis reumatoide. Reumatología Clínica 16:4, pages 272-281.
Crossref
M Verstappen, E van Mulligen, P H P de Jong & A H M van der Helm-Van Mil. (2020) DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability. RMD Open 6:1, pages e001220.
Crossref
Lukas Schlager, Michaela Loiskandl, Daniel Aletaha & Helga Radner. (2020) Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. Rheumatology 59:2, pages 324-334.
Crossref
Yasmine F. Ibrahim, Rabab A. Moussa, Asmaa M. A. Bayoumi & Al-Shaimaa F. Ahmed. (2019) Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-κB/JNK: a possible role of P-glycoprotein. Inflammopharmacology 28:1, pages 215-230.
Crossref
S Chandrashekara, DeepakChikkulikere Lingaraju, P Renuka & KR Anupama. (2020) Potential of neutrophil to lymphocyte ratio in predicting sustained remission in rheumatoid arthritis compared to other immune activation markers. Indian Journal of Medical Research 152:3, pages 234.
Crossref
L. E. Burgers, J. A. van der Pol, T. W. J. Huizinga, C. F. Allaart & A. H. M. van der Helm-van Mil. (2019) Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care. Arthritis Research & Therapy 21:1.
Crossref
Kentaro Chino, Tsuneo Kondo, Ryota Sakai, Shuntaro Saito, Yusuke Okada, Akiko Shibata, Takahiko Kurasawa, Ayumi Okuyama, Hirofumi Takei & Koichi Amano. (2019) Tocilizumab monotherapy for polymyalgia rheumatica: A prospective, single‐center, open‐label study. International Journal of Rheumatic Diseases 22:12, pages 2151-2157.
Crossref
Yuichi Maeda & Kiyoshi Takeda. (2019) Host–microbiota interactions in rheumatoid arthritis. Experimental & Molecular Medicine 51:12, pages 1-6.
Crossref
Carmen Tze Kwan Ho, Chi Chiu Mok, Tommy Tsang Cheung, Kitty Yan Kwok & Ronald Man Lung Yip. (2019) Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology. Clinical Rheumatology 38:12, pages 3331-3350.
Crossref
Christoph T Berger, Birke Rebholz-Chaves, Mike Recher, Tobias Manigold & Thomas Daikeler. (2019) Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses. Annals of the Rheumatic Diseases 78:7, pages 1012-1014.
Crossref
Shuzo Yoshida, Takuya Kotani, Yuko Kimura, Yoko Matsumura, Ayaka Yoshikawa, Nao Tokai, Takuro Ozaki, Koji Nagai, Toru Takeuchi, Shigeki Makino & Shigeki Arawaka. (2019) Efficacy of abatacept tapering therapy for sustained remission in patients with rheumatoid arthritis: Prospective single-center study. International Journal of Rheumatic Diseases 22:1, pages 81-89.
Crossref
Yosuke Hattori, Daihei Kida & Atsushi Kaneko. (2017) Normal serum matrix metalloproteinase-3 levels can be used to predict clinical remission and normal physical function in patients with rheumatoid arthritis. Clinical Rheumatology 38:1, pages 181-187.
Crossref
Motomu Hashimoto, Moritoshi Furu, Wararu Yamamoto, Takanori Fujimura, Ryota Hara, Masaki Katayama, Akira Ohnishi, Kengo Akashi, Shuzo Yoshida, Koji Nagai, Yonsu Son, Hideki Amuro, Toru Hirano, Kosuke Ebina, Ryuji Uozumi, Hiromu Ito, Masao Tanaka, Koichiro Ohmura, Takao Fujii & Tsuneyo Mimori. (2018) Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Research & Therapy 20:1.
Crossref
Bruno Fautrel. (2018) Therapeutic strategy for rheumatoid arthritis patients who have achieved remission. Joint Bone Spine 85:6, pages 679-685.
Crossref
Maxime Samson, Hervé Devilliers, Kim Heang Ly, François Maurier, Boris Bienvenu, Benjamin Terrier, Pierre Charles, Loïc Guillevin, Jean-François Besancenot, Eric Liozon, Anne Laure Fauchais, Romaric Loffroy, Christine Binquet, Sylvain Audia, Raphaèle Seror, Xavier Mariette & Bernard Bonnotte. (2018) Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study. European Journal of Internal Medicine 57, pages 96-104.
Crossref
Yuko Kaneko, Masaru Kato, Yoshiya Tanaka, Masayuki Inoo, Hitomi Kobayashi-Haraoka, Koichi Amano, Masayuki Miyata, Yohko Murakawa, Hidekara Yasuoka, Shintaro Hirata, Eiichi Tanaka, Nobuyuki Miyasaka, Hisashi Yamanaka, Kazuhiko Yamamoto & Tsutomu Takeuchi. (2018) Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). Annals of the Rheumatic Diseases 77:9, pages 1268-1275.
Crossref
Simon Wing-Fai Mok, Betty Yuen-Kwan Law, Vincent Kam-Wai Wong & Liang Liu. 2018. Immunoregulatory Aspects of Immunotherapy. Immunoregulatory Aspects of Immunotherapy.
E. L. Nasonov, M. L. Stanislav, V. I. Mazurov, T. M. Chernykh, V. N. Sorotskaya, T. S. Salnikova, R. S. Saikovsky, O. V. Reshet’ko, T. A. Popova, E. I. Shmidt, V. P. Tyurin, N. P. Shilkina, I. N. Bokarev, M. Z. Kanevskaya & S. S. Yakushin. (2018) LONG-TERM SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS OF MODERATE OR HIGH ACTIVITY (RESULTS OF PHASE III MULTICENTER EXTENSION CLINICAL STUDY ML28124). Rheumatology Science and Practice 56:3, pages 280-285.
Crossref
E. L. Nasonov, Yu. A. Olyunin & A. M. Lila. (2018) RHEUMATOID ARTHRITIS: THE PROBLEMS OF REMISSION AND THERAPY RESISTANCE. Rheumatology Science and Practice 56:3, pages 263-271.
Crossref
Cesar Diaz-Torne, Maria dels Angels Ortiz, Patricia Moya, Maria Victoria Hernandez, Delia Reina, Ivan Castellvi, Juan Jose De Agustin, Diana de la Fuente, Hector Corominas, Raimon Sanmarti, Carlos Zamora, Elisabet Cantó & Silvia Vidal. (2018) The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab. Seminars in Arthritis and Rheumatism 47:6, pages 757-764.
Crossref
Emma Simpson, Emma Hock, Matt Stevenson, Ruth Wong, Naila Dracup, Allan Wailoo, Philip Conaghan, Cristina Estrach, Christopher Edwards & Richard Wakefield. (2018) What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis. Health Technology Assessment 22:20, pages 1-258.
Crossref
S. Ishikawa, M. Tasaki, T. Kuroda, D. Kobayashi, K. Saito, Y. Nakagawa, M. Ikeda, K. Takahashi & Y. Tomita. (2018) Management of Juvenile Idiopathic Arthritis in ABO-incompatible Kidney Transplantation: A Case Report. Transplantation Proceedings 50:3, pages 869-872.
Crossref
Bruno Fautrel. (2018) Que faire une fois la rémission obtenue dans la polyarthrite rhumatoïde. Revue du Rhumatisme Monographies 85:1, pages 25-31.
Crossref
Chantal A M Bouman, Lieke Tweehuysen, Dieneke Haverkort, Cornelia H van den Ende, Aatke van der Maas & Alfons A den Broeder. (2018) Abatacept and tocilizumab tapering in rheumatoid arthritis patients: results of SONATA—a retrospective, exploratory cohort study. Rheumatology Advances in Practice 2:1.
Crossref
Christopher J Edwards, Bruno Fautrel, Hendrik Schulze-Koops, Tom W J Huizinga & Klaus Kruger. (2017) Dosing down with biologic therapies: a systematic review and clinicians’ perspective. Rheumatology 56:11, pages 1847-1856.
Crossref
Femke B. Lamers-Karnebeek, Jolanda J. Luime, David F. Ten Cate, Steven Teerenstra, Nanno W. A. A. Swen, Andreas H. Gerards, Jos Hendrikx, Emma M. van Rooyen, Ramon Voorneman, Cees Haagsma, Natalja Basoski, Mike de Jager, Marjan Ghiti Moghadam, Monique N. Efde, Yvonne P. M. Goekoop-Ruiterman, Piet L. C. M. van Riel, Johannes W. G. Jacobs & Tim L. Jansen. (2017) Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors. Rheumatology 56:9, pages 1560-1565.
Crossref
Lise M. Verhoef, Lieke Tweehuysen, Marlies E. Hulscher, Bruno Fautrel & Alfons A. den Broeder. (2017) bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search. Rheumatology and Therapy 4:1, pages 1-24.
Crossref
Shuntaro Saito, Yuko Kaneko, Keisuke Izumi & Tsutomu Takeuchi. (2017) Utility of Dose Frequency Adjustment in Tocilizumab Administration for Rheumatoid Arthritis. The Journal of Rheumatology 44:5, pages 553-557.
Crossref
A. Mallick, B. Fautrel, F. Sagez, C. Sordet, R.-M. Javier, H. Petit, E. Chatelus, N. Rahal, J.-E. Gottenberg & J. Sibilia. (2017) Stratégies d’arrêt ou de réduction des biomédicaments dans la polyarthrite rhumatoïde en rémission. La Revue de Médecine Interne 38:4, pages 256-263.
Crossref
Antoine Vanier, Xavier Mariette, Florence Tubach & Bruno Fautrel. (2017) Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial. Value in Health 20:4, pages 577-585.
Crossref
D. Aletaha & A. Kerschbaumer. (2017) Rheumatoide ArthritisRheumatoid arthritis. Zeitschrift für Rheumatologie 76:1, pages 8-14.
Crossref
Lieke Tweehuysen, Cornelia H. van den Ende, Fenna M. M. Beeren, Evelien M. J. Been, Frank H. J. van den Hoogen & Alfons A. den Broeder. (2017) Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review. Arthritis & Rheumatology 69:2, pages 301-308.
Crossref
Aleksander Lenert & Petar Lenert. (2016) Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice. Clinical Rheumatology 36:1, pages 1-8.
Crossref
Georg Schett, Paul Emery, Yoshiya Tanaka, Gerd Burmester, David S Pisetsky, Esperanza Naredo, Bruno Fautrel & Ronald van Vollenhoven. (2016) Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Annals of the Rheumatic Diseases 75:8, pages 1428-1437.
Crossref
Bruno Fautrel, Thao Pham, Toni Alfaiate, Frédérique Gandjbakhch, Violaine Foltz, Jacques Morel, Emmanuelle Dernis, Philippe Gaudin, Olivier Brocq, Elisabeth Solau-Gervais, Jean-Marie Berthelot, Jean-Charles Balblanc, Xavier Mariette & Florence Tubach. (2016) Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) . Annals of the Rheumatic Diseases 75:1, pages 59-67.
Crossref
Kazuki Yoshida, Helga Radner, Maria D. Mjaavatten, Jeffrey D. Greenberg, Arthur Kavanaugh, Mitsumasa Kishimoto, Kazuo Matsui, Masato Okada, George Reed, Yukihiko Saeki, Shigeto Tohma, Joel Kremer & Daniel H. Solomon. (2015) Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study. The Journal of Rheumatology 42:12, pages 2238-2246.
Crossref
György Nagy & Ronald F van Vollenhoven. (2015) Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?. Arthritis Research & Therapy 17:1.
Crossref
Tetsuo Kobayashi, Satoshi Ito, Daisuke Kobayashi, Anri Kojima, Atsushi Shimada, Ichiei Narita, Akira Murasawa, Kiyoshi Nakazono & Hiromasa Yoshie. (2015) Interleukin‐6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors. Clinical and Experimental Dental Research 1:2, pages 63-73.
Crossref
T. Martijn Kuijper, Femke B.G. Lamers-Karnebeek, Johannes W.G. Jacobs, Johanna M.W. Hazes & Jolanda J. Luime. (2015) Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review. The Journal of Rheumatology 42:11, pages 2012-2022.
Crossref
Raimon Sanmartí, Susana García-Rodríguez, José María Álvaro-Gracia, José Luis Andreu, Alejandro Balsa, Rafael Cáliz, Antonio Fernández-Nebro, Iván Ferraz-Amaro, Juan Jesús Gómez-Reino, Isidoro González-Álvaro, Emilio Martín-Mola, Víctor Manuel Martínez-Taboada, Ana M. Ortiz, Jesús Tornero, Sara Marsal & José Vicente Moreno-Muelas. (2015) 2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the Use of Biological Therapies in Rheumatoid Arthritis. Reumatología Clínica (English Edition) 11:5, pages 279-294.
Crossref
Raimon Sanmart?Susana Garc?a-Rodr?guez, Jos? Mar?a ?lvaro-Gracia, Jos? Luis Andreu, Alejandro Balsa, Rafael C?liz, Antonio Fern?ndez-Nebro, Iv?n Ferraz-Amaro, Juan Jes?s G?mez-Reino, Isidoro Gonz?lez-?lvaro, Emilio Mart?n-Mola, V?ctor Manuel Mart?nez-Taboada, Ana M. Ortiz, Jes?s Tornero, Sara Marsal & Jos? Vicente Moreno-Muelas. (2015) Actualizaci?n 2014 del Documento de Consenso de la Sociedad Espa?ola de Reumatolog?a sobre el uso de terapias biol?gicas en la artritis reumatoide. Reumatolog?a Cl?nica 11:5, pages 279-294.
Crossref
Bruno Fautrel & Alfons A. den Broeder. (2015) De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?. Best Practice & Research Clinical Rheumatology 29:4-5, pages 550-565.
Crossref
Arthur Kavanaugh, Susan J Lee, Jeffrey R Curtis, Jeffrey D Greenberg, Joel M Kremer, Lilian Soto, Carol J Etzel, Vanessa Cox, Kazuki Yoshida, George W Reed & Daniel H Solomon. (2015) Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. Annals of the Rheumatic Diseases 74:6, pages 1150-1155.
Crossref
Yoh Arita, Yoshikazu Nakaoka, Michio Otsuki, Kaori Higuchi, Takahiro Hashimoto-Kataoka, Taku Yasui, Takeshi Masaki, Tomohito Ohtani, Tadamitsu Kishimoto, Keiko Yamauchi-Takihara, Issei Komuro & Yasushi Sakata. (2015) Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis. International Journal of Cardiology 187, pages 319-321.
Crossref
Atsushi Ogata, Takayoshi Morita, Yuji Yoshida & Toshio Tanaka. (2015) Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis. Therapeutic Delivery 6:3, pages 283-295.
Crossref
Stefan Siebert, Alexander Tsoukas, Jamie Robertson & Iain McInnes. (2015) Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases. Pharmacological Reviews 67:2, pages 280-309.
Crossref
Yusuke Tozawa, Shouji Fujita, Shuji Abe, Koichi Kitamura & Ichiro Kobayashi. (2015) Radiological improvement by tocilizumab in polyarticular juvenile idiopathic arthritis. Pediatrics International 57:2, pages 307-310.
Crossref
T. Takeuchi, T. Matsubara, S. Ohta, M. Mukai, K. Amano, S. Tohma, Y. Tanaka, H. Yamanaka & N. Miyasaka. (2014) Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Rheumatology 54:4, pages 683-691.
Crossref
Timo Rath, Ulrike Billmeier, Maximilian J. Waldner, Raja Atreya & Markus F. Neurath. (2015) From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Archives of Toxicology 89:4, pages 541-554.
Crossref
Paul Emery, Gerd R Burmester, Vivian P Bykerk, Bernard G Combe, Daniel E Furst, Emilie Barré, Chetan S Karyekar, Dennis A Wong & Tom W J Huizinga. (2015) Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases 74:1, pages 19-26.
Crossref
Takeshi Suzuki, Tomoya Hirota, Hiroshi Ogishima, Naoto Umeda, Yuya Kondo, Masahiro Yokosawa, Haruka Miki, Hiroto Tsuboi, Isao Matsumoto & Takayuki Sumida. (2015) Subclinical inflammation with tocilizumab treatment of rheumatoid arthritis: MRI evaluation for 2 years. International Journal of Rheumatic Diseases 18:1, pages 108-110.
Crossref
Yoshiya Tanaka & Shintaro Hirata. (2014) Intensive Intervention Can Lead to a Treatment Holiday from Biological DMARDs in Patients with Rheumatoid Arthritis. Drugs 74:18, pages 2129-2139.
Crossref
Marie Fechtenbaum, Jackie L Nam & Paul Emery. (2014) Biologics in rheumatoid arthritis: where are we going?. British Journal of Hospital Medicine 75:8, pages 448-456.
Crossref
Norihiro Nishimoto. (2014) 8. Pharmacotherapy of Rheumatoid Arthritis-interleukin-6 Blocker Made in Japan-. Nihon Naika Gakkai Zasshi 103:3, pages 665-673.
Crossref
Delphine Dénarié, Elodie Constant, Thierry Thomas & Hubert Marotte. (2014) Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?. Mediators of Inflammation 2014, pages 1-7.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.